KETOROLAC TROMETHAMINE- ketorolac tromethamine injection, solution 
McKesson Packaging Services Business Unit of McKesson Corporation


Ketorolac Tromethamine Injection, USP
60 mg (30 mg/mL)

Rx only
Revised: 01/2007


Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days) management of moderately severe acute pain that requires analgesia at the opioid level. It is NOT indicated for minor or chronic painful conditions. Ketorolac tromethamine is a potent NSAID analgesic, and its administration carries many risks. The resulting NSAID-related adverse events can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately. Increasing the dose of ketorolac tromethamine beyond the label recommendations will not provide better efficacy but will result in increasing the risk of developing serious adverse events.

Gastrointestinal Effects

Renal Effects

Risk of Bleeding


Intrathecal or Epidural Administration

Labor, Delivery and Nursing

Concomitant Use with NSAIDs


Ketorolac Tromethamine Tablets

Special Populations


Ketorolac tromethamine is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs). The chemical name for ketorolac tromethamine is (±)-5-benzoyl-2, 3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol, and the structural formula is presented in Figure 1.

Figure 1

structural formula

Ketorolac tromethamine is a racemic mixture of [-]S and [+]R ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. Ketorolac tromethamine has a pKa of 3.5 and an n-octanol/water partition coefficient of 0.26. The molecular weight of ketorolac tromethamine is 376.41.

Ketorolac tromethamine is available for intravenous (IV) or intramuscular (IM) administration as 15 mg per mL (1.5%) and 30 mg per mL (3%) in sterile solution; 60 mg per 2 mL (3%) of ketorolac tromethamine in sterile solution is available for IM administration only. The solutions contain 10% (w/v) alcohol, and 6.68 mg, 4.35 mg, and 8.7 mg, respectively, of sodium chloride in sterile water. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment, pH 7.4 (6.9 to 7.9). The sterile solutions are clear and slightly yellow in color.



Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID). Ketorolac tromethamine inhibits synthesis of prostaglandins and may be considered a peripherally-acting analgesic. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.

Pain relief was statistically different after ketorolac tromethamine dosing from that of placebo at 1/2 hour (the first time point at which it was measured) following the largest recommended doses of ketorolac tromethamine, and by 1 hour following the smallest recommended doses. The peak analgesic effect occurred within 2 to 3 hours and was not statistically significantly different over the recommended dosage range of ketorolac tromethamine. The greatest difference between large and small doses of ketorolac tromethamine by either route was in the duration of analgesia.


Ketorolac tromethamine is a racemic mixture of [-]S- and [+]R-enantiomeric forms, with the S-form having analgesic activity.

Comparison of IV, IM and Oral Pharmacokinetics

The pharmacokinetics of ketorolac tromethamine, following IV, IM, and oral doses of ketorolac tromethamine, are compared in Table 1. The extent of bioavailability following administration of the oral and IM forms of ketorolac tromethamine was equal to that following an IV bolus.

Linear Kinetics

Following administration of single oral, IM or IV dose of ketorolac tromethamine, in the recommended dosage ranges, the clearance of the racemate does not change. This implies that the pharmacokinetics of ketorolac tromethamine in humans, following single or multiple IM, IV, or recommended oral doses of ketorolac tromethamine, are linear. At the higher recommended doses, there is a proportional increase in the concentrations of free and bound racemate.

Binding and Distribution

The ketorolac tromethamine racemate has been shown to be highly protein-bound (99%). Nevertheless, even plasma concentrations as high as 10 mcg/mL will only occupy approximately 5% of the albumin binding sites. Thus, the unbound fraction for each enantiomer will be constant over the therapeutic range. A decrease in serum albumin, however, will result in increased free drug concentrations.

The mean apparent volume (Vβ) of ketorolac tromethamine following complete distribution was approximately 13 liters. This parameter was determined from single-dose data.


Ketorolac tromethamine is largely metabolized in the liver. The metabolic products are hydroxylated and conjugated forms of the parent drug. The products of metabolism, and some unchanged drug, are excreted in the urine.

Clearance and Excretion

A single-dose study with 10 mg ketorolac tromethamine (n=9) demonstrated that the S-enantiomer is cleared approximately two times faster than the R-enantiomer, and that the clearance was independent of the route of administration. This means that the ratio of S/R plasma concentrations decreases with time after each dose. There is little or no inversion of the R- to S- form in humans. The clearance of the racemate in normal subjects, elderly individuals, and in hepatically and renally impaired patients, is outlined in Table 2.

The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD±0.4) compared with 5 hours (SD±1.7) for the R-enantiomer. In other studies, the half-life for the racemate has been reported to lie within the range of 5 - 6 hours.

Table 1
Table of Approximate Average Pharmacokinetic Parameters (Mean±SD) Following Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine

Oral † Intramuscular* Intravenous Bolus‡
Pharmacokinetic Parameters (units) 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg
Bioavailability (extent) 100%
Tmax1 (min) 44±34 33±21** 44±29 33±21** 1.1±0.7** 2.9±1.8
Cmax2 (mcg/mL) [Single-dose] 0.87±0.22 1.14±0.32** 2.42±0.68 4.55±1.27** 2.47±0.51** 4.65±0.96
Cmax (mcg/mL) [steady state qid] 1.05±0.26** 1.56±0.44** 3.11±0.87** N/A†† 3.09±1.17** 6.85±2.61
Cmin3 (mcg/mL) [steady state qid] 0.29±0.07** 0.47±0.13** 0.93±0.26** N/A 0.61±0.21** 1.04±0.35
Cavg4 (mcg/mL) [steady state qid] 0.59±0.2** 0.94±0.29** 1.88±0.59** N/A 1.09±0.3** 2.17±0.59
Vß5 (L/kg) ———— 0.175±0.039 ———— 0.210±0.044
% Dose metabolized = <50
% Dose excreted in urine = 91
% Dose excreted in feces = 6
% Plasma protein binding = 99
1Time-to-peak plasma concentration
2Peak plasma concentration
3Trough plasma concentration
4Average plasma concentration
5Volume of distribution

†Derived from PO pharmacokinetic studies in 77 normal fasted volunteers

*Derived from IM pharmacokinetic studies in 54 normal volunteers

‡Derived from IV pharmacokinetic studies in 24 normal volunteers

††Not applicable because 60 mg is only recommended as a single dose

**Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficient of variation for observed Cmax and Tmax data

Table 2

The Influence of Age, Liver and Kidney Function, on the Clearance and Terminal Half-life of Ketorolac

Tromethamine (IM1 and ORAL2)
Total Clearance [in L/h/kg]3 Terminal Half-life [in hours]
Type of Subjects


Mean (range)


Mean (range)


Mean (range)


Mean (range)

Normal Subjects

IM (n=54)

mean age=32, range=18-60

Oral (n=77)

mean age=32, range=20-60









Healthy Elderly Subjects

IM (n=13), Oral (n=12)

mean age=72, range=65-78









Patients with Hepatic Dysfunction

IM and Oral (n=7)

mean age=51, range=43-64









Patients with Renal Impairment

IM (n=25), Oral (n=9)

serum creatinine=1.9-5.0 mg/dL,

mean age (IM)=54, range=35-71

mean age (Oral)=57, range=39-70









Renal Dialysis Patients

IM and Oral (n=9)

mean age=40, range=27-63




1Estimated from 30 mg single IM doses of ketorolac tromethamine 2Estimated from 10 mg single oral doses of ketorolac tromethamine

IV-Administration: In normal subjects (n=37), the
total clearance of 30 mg

IV-administered Ketorolac Tromethamine was 0.030
(0.017-0.051) L/h/kg.

The terminal half-life was 5.6 (4.0-7.9) hours


Ketorolac tromethamine administered as an IV bolus every 6 hours for 5 days to healthy subjects (n=13), showed no significant difference in Cmax on Day 1 and Day 5. Trough levels averaged 0.29 mcg/mL (SD±0.13) on Day 1 and 0.55 mcg/mL (SD±0.23) on Day 6. Steady state was approached after the fourth dose.

Accumulation of ketorolac tromethamine has not been studied in special populations (geriatric, pediatric, renal failure or hepatic disease patients).

Kinetics in Special Populations

Elderly Patients

Based on single-dose data only, the half-life of the ketorolac tromethamine racemate increased from 5 to 7 hours in the elderly (65 - 78 years) compared with young healthy volunteers (24 - 35 years) (see Table 2). There was little difference in the Cmax for the two groups (elderly, 2.52 mcg/mL±0.77; young, 2.99 mcg/mL±1.03) (see PRECAUTIONS − Use in the Elderly).

Renally Impaired Patients

Based on single-dose data only, the mean half-life of ketorolac tromethamine in renally impaired patients is between 6 and 19 hours and is dependent on the extent of the impairment. There is poor correlation between creatinine clearance and total ketorolac tromethamine clearance in the elderly and populations with renal impairment (r=0.5).

In patients with renal disease, the AUC of each enantiomer increased by approximately 100% compared with healthy volunteers. The volume of distribution doubles for the S-enantiomer and increases by 1/5th for the R-enantiomer. The increase in volume of distribution of ketorolac tromethamine implies an increase in unbound fraction.

The AUC ratio of the ketorolac tromethamine enantiomers in healthy subjects and patients remained similar, indicating there was no selective excretion of either enantiomer in patients compared to healthy subjects (see WARNINGS– Renal Effects).

Hepatic Effects

There was no significant difference in estimates of half-life, AUC, Cmax, in 7 patients with liver disease compared to healthy volunteers (see PRECAUTIONS – Hepatic Effects).


The analgesic efficacy of intramuscularly, intravenously, and orally administered ketorolac tromethamine was investigated in two postoperative pain models: general surgery (orthopedic, gynecologic and abdominal) and oral surgery (removal of impacted third molars). The studies were double-blind, single- and multiple-dose, parallel trial designs in patients with moderate to severe pain at baseline. Ketorolac tromethamine injection was compared as follows: IM to meperidine or morphine administered intramuscularly, and IV to morphine administered either directly IV or through a PCA (Patient-Controlled Analgesia) pump.

Short-term Use (up to 5 days) Studies

In the comparisons of intramuscular administration during the first hour, the onset of analgesic action was similar for ketorolac tromethamine and the narcotics, but the duration of analgesia was longer with ketorolac tromethamine than with the opioid comparators meperidine or morphine.

In a multi-dose, postoperative (general surgery) double-blind trial of ketorolac tromethamine 30 mg IM versus morphine 6 and 12 mg IM, each drug given on an “as needed” basis for up to 5 days, the overall analgesic effect of ketorolac tromethamine 30 mg IM was between that of morphine 6 and 12 mg. The majority of patients treated with either ketorolac tromethamine or morphine were dosed for up to 3 days; a small percentage of patients received 5 days of dosing.

In clinical settings where perioperative morphine was allowed, ketorolac tromethamine 30 mg IV, given once or twice as needed, provided analgesia comparable to morphine 4 mg IV once or twice as needed.

There was relatively limited experience with 5 consecutive days of ketorolac tromethamine IV use in controlled clinical trials, as most patients were given the drug for 3 days or less. The adverse events seen with IV-administered ketorolac tromethamine were similar to those observed with IM-administered ketorolac tromethamine, as would be expected based on the similar pharmacokinetics and bioequivalence (AUC, clearance, plasma half-life) of IV and IM routes of ketorolac tromethamine administration.

Clinical Studies with Concomitant Use of Opioids

Clinical studies in postoperative pain management have demonstrated that ketorolac tromethamine injection, when used in combination with opioids, significantly reduced opioid consumption. This combination may be useful in the subpopulation of patients especially prone to opioid-related complications. Ketorolac tromethamine and narcotics should not be administered in the same syringe.

In a postoperative study, where all patients received morphine by a PCA device, patients treated with ketorolac tromethamine IV as fixed intermittent boluses (e.g., 30 mg initial dose followed by 15 mg q3h), required significantly less morphine (26%) than the placebo group. Analgesia was significantly superior, at various postdosing pain assessment times, in the patients receiving ketorolac tromethamine IV plus PCA morphine as compared to patients receiving PCA-administered morphine alone.

Postmarketing Surveillance Study

A large postmarketing observational, non-randomized study, involving approximately 10,000 patients receiving ketorolac tromethamine, demonstrated that the risk of clinically serious gastrointestinal (G.I.) bleeding was dose-dependent (see Table 3A and 3B.) This was particularly true in elderly patients who received an average daily dose greater than 60 mg/day of ketorolac tromethamine (Table 3A).

Table 3

Incidence of Clinically Serious G.I. Bleeding as Related to Age,
Total Daily Dose, and History of G.I. Perforation, Ulcer, Bleeding (PUB)
after up to 5 Days of Treatment with Ketorolac Tromethamine Injection

A. Patients without History of PUB
Age of Patients Total Daily Dose of Ketorolac Tromethamine Injection
≤60 mg >60 to 90 mg >90 to 120 mg >120 mg
<65 years of age 0.4% 0.4% 0.9% 4.6%
≥65 years of age 1.2% 2.8% 2.2% 7.7%
B. Patients with History of PUB
Age of Patients Total Daily Dose of Ketorolac Tromethamine Injection
≤60 mg >60 to 90 mg >90 to 120 mg >120 mg
<65 years of age 2.1% 4.6% 7.8% 15.4%
≥65 years of age 4.7% 3.7% 2.8% 25%


Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with ketorolac tromethamine injection, and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary. Combined use of ketorolac tromethamine injection and tablets is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE AND ADMINISTRATION, and ADVERSE REACTIONS). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.

Ketorolac tromethamine injection has been used concomitantly with morphine and meperidine, and has shown an opioid-sparing effect. For breakthrough pain, it is recommended to supplement the lower end of the ketorolac tromethamine injection dosage range with low doses of narcotics prn, unless otherwise contraindicated. Ketorolac tromethamine injection and narcotics should not be administered in the same syringe (see DOSAGE AND ADMINISTRATION Pharmaceutical Information for Ketorolac Tromethamine Injection).


(see also Boxed WARNING)


(see also Boxed WARNING)

► The combined use of ketorolac tromethamine injection and tablets is not to exceed 5 days.

The most serious risks associated with ketorolac tromethamine are:

Renal Effects: Ketorolac tromethamine and its metabolites are eliminated primarily by the kidneys, which, in patients with reduced creatinine clearance, will result in diminished clearance of the drug (see CLINICAL PHARMACOLOGY). Therefore, ketorolac tromethamine should be used with caution in patients with impaired renal function (see DOSAGE AND ADMINISTRATION) and such patients should be followed closely. With the use of ketorolac tromethamine, there have been reports of acute renal failure, nephritis, and nephrotic syndrome.

Because patients with underlying renal insufficiency are at increased risk of developing acute renal failure, the risks and benefits should be assessed prior to giving ketorolac tromethamine to these patients. Hence, in patients with moderately elevated serum creatinine, it is recommended that the daily dose of ketorolac tromethamine injection be reduced by half, not to exceed 60 mg/day. Ketorolac tromethamine is CONTRAINDICATED IN PATIENTS WITH SERUM CREATININE CONCENTRATIONS INDICATING ADVANCED RENAL IMPAIRMENT (see CONTRAINDICATIONS).

Hypovolemia should be corrected before treatment with ketorolac tromethamine is initiated.

In postmarking experience, postoperative hematomas and other signs of wound bleeding have been reported in association with the perioperative use of ketorolac tromethamine injection. Therefore, perioperative use of ketorolac tromethamine should be avoided and postoperative use be undertaken with caution when hemostasis is critical (see WARNINGS and PRECAUTIONS).



  • Hepatic Effects: Ketorolac tromethamine should be used with caution in patients with impaired hepatic function, or a history of liver disease. Treatment with ketorolac tromethamine may cause elevations of liver enzymes, and in patients with pre-existing liver dysfunction it may lead to the development of a more severe hepatic reaction. The administration of ketorolac tromethamine should be discontinued in patients in whom an abnormal liver test has occurred as a result of ketorolac tromethamine therapy.
  • Hematologic Effects: Ketorolac tromethamine inhibits platelet aggregation and may prolong bleeding time; therefore, it is contraindicated as a preoperative medication and caution should be used when hemostasis is critical. Unlike aspirin, the inhibition of platelet function by ketorolac tromethamine disappears within 24 to 48 hours after the drug is discontinued. Ketorolac tromethamine does not appear to affect platelet count, prothrombin time (PT) or partial thromboplastin time (PTT). In controlled clinical studies, where ketorolac tromethamine was administered intramuscularly or intravenously postoperatively, the incidence of clinically significant postoperative bleeding was 0.4% for ketorolac tromethamine compared to 0.2% in the control groups receiving narcotic analgesics.


Ketorolac tromethamine is a potent NSAID and may cause serious side effects such as gastrointestinal bleeding or kidney failure, which may result in hospitalization and even fatal outcome.

Physicians, when prescribing ketorolac tromethamine, should inform their patients or their guardians of the potential risks of ketorolac tromethamine treatment (see Boxed WARNING, WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS sections). Advise patients not to give ketorolac tromethamine tablets to other family members and to discard any unused drug.

Remember that the total duration of ketorolac tromethamine therapy is not to exceed 5 (five) days in adults or a single dose in pediatric patients ages 2 to 16 years.


Ketorolac is highly bound to human plasma protein (mean 99.2%).

The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 mcg/mL. Ketorolac does not alter digoxin protein binding. In vitro studies indicate that, at therapeutic concentrations of salicylate (300 mcg/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential two-fold increase in unbound ketorolac plasma levels. Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam,acetaminophen, phenytoin, and tolbutamide did not alter ketorolac tromethamine protein binding.

In a study involving 12 volunteers, ketorolac tromethamine tablets were co-administered with a single dose of 25 mg warfarin, causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin. In another study, ketorolac tromethamine injection was given with two doses of 5000 U of heparin to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 - 11.4 min) compared to a mean of 6.0 minutes (3.4 - 7.5 min) for heparin alone and 5.1 minutes (3.5 - 8.5 min) for placebo. Although these results do not indicate a significant interaction between ketorolac tromethamine and warfarin or heparin, the administration of ketorolac tromethamine to patients taking anticoagulants should be done extremely cautiously and patients should be closely monitored (see WARNINGS and PRECAUTIONS).

Ketorolac tromethamine injection reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).

Concomitant administration of ketorolac tromethamine tablets and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately 3-fold from 5.4 to 17.8 mcg/h/mL) and terminal half-life increased approximately 2-fold from 6.6 to 15.1 hours. Therefore, concomitant use of ketorolac tromethamine and probenecid is contraindicated.

Inhibition of renal lithium clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs. The effect of ketorolac tromethamine on plasma lithium has not been studied, but cases of increased lithium plasma levels during ketorolac tromethamine therapy have been reported.

Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate. The effect of ketorolac tromethamine on methotrexate clearance has not been studied.

In postmarketing experience, there have been reports of a possible interaction between ketorolac tromethamine injection and non-depolarizing muscle relaxants that resulted in apnea. The concurrent use of ketorolac tromethamine with muscle relaxants has not been formally studied.

Concomitant use of ACEinhibitors may increase the risk of renal impairment, particularly in volume depleted patients.

Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs(phenytoin, carbamazepine).

Hallucinations have been reported when ketorolac tromethamine was used in patients taking psychoactive drugs(fluoxetine, thiothixene, alprazolam).

Ketorolac tromethamine injection has been administered concurrently with morphine in several clinical trials of postoperative pain without evidence of adverse interactions. Do not mix ketorolac tromethamine and morphine in the same syringe.

There is no evidence, in animal or human studies, that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

An 18-month study in mice with ketorolac tromethamine tablets at 2 mg/kg/day (0.9 times the human systemic exposure at the recommended IM or IV dose of 30 mg qid, based on area-under-the-plasma concentration curve [AUC]), and a 24-month study in rats at 5 mg/kg/day (0.5 times the human AUC), showed no evidence of tumorigenicity.

Ketorolac tromethamine was not mutagenic in the Ames test, unscheduled DNA synthesis and repair, and in forward mutation assays. Ketorolac tromethamine did not cause chromosome breakage in the in vivo mouse micronucleus assay. At 1590 mcg/mL and at higher concentrations, ketorolac tromethamine increased the incidence of chromosomal aberrations in Chinese hamster ovarian cells.

Impairment of fertility did not occur in male or female rats at oral doses of 9 mg/kg (0.9 times the human AUC) and 16 mg/kg (1.6 times the human AUC) of ketorolac tromethamine, respectively.


Pregnancy Category C. Reproduction studies have been performed during organogenesis, using daily doses of ketorolac tromethamine tablets at 3.6 mg/kg (0.37 times the human AUC) in rabbits and at 10 mg/kg (1 times the human AUC) in rats. Results of these studies did not reveal evidence of teratogenicity to the fetus. Doses of ketorolac tromethamine tablets at 1.5 mg/kg (0.14 times the human AUC), administered after gestation day 17, caused dystocia and higher pup mortality in rats. There are no adequate and well-controlled studies of ketorolac tromethamine in pregnant women. Ketorolac tromethamine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Labor and Delivery

The use of ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine musculature, thus increasing the risk of uterine hemorrhage (see CONTRAINDICATIONS).

Lactation and Nursing

After a single administration of a 10 mg ketorolac tromethamine tablet to humans, the maximum milk concentration observed was 7.3 ng/mL and the maximum milk-to-plasma ratio was 0.037. After one day of dosing (qid), the maximum milk concentration was 7.9 ng/mL and the maximum milk-to-plasma ratio was 0.025. Because of the possible adverse effects of prostaglandin-inhibiting drugs on neonates, use in nursing mothers is CONTRAINDICATED.

Pediatric Use

Safety and efficacy in pediatric patients (less than 16 years of age) have not been established. Therefore, use of ketorolac tromethamine in pediatric patients is not recommended.

Use in the Elderly (≥65 Years of Age)

Because ketorolac tromethamine may be cleared more slowly by the elderly (see CLINICAL PHARMACOLOGY) who are also more sensitive to the adverse effects of NSAIDs (see WARNINGS − Renal Effects), extra caution and reduced dosages (see DOSAGE AND ADMINISTRATION) must be used when treating the elderly with ketorolac tromethamine injection. The lower end of the ketorolac tromethamine injection dosage range is recommended for patients over 65 years of age and total daily dose is not to exceed 60 mg. The incidence and severity of gastrointestinal complications increases with increasing dose of, and duration of treatment with, ketorolac tromethamine.


Adverse reaction rates increase with higher doses of ketorolac tromethamine. Practitioners should be alert for the severe complications of treatment with ketorolac tromethamine, such as G.I. ulceration, bleeding and perforation, postoperative bleeding, acute renal failure, anaphylactic and anaphylactoid reactions, and liver failure (see Boxed WARNING, WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION). These NSAID-related complications can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately.

The adverse reactions listed below were reported in clinical trials as probably related to ketorolac tromethamine.

The following adverse events were reported from postmarketing experience.

Body as a Whole: hypersensitivity reactions such as anaphylaxis, anaphylactoid reaction, laryngeal edema, tongue edema (see Boxed WARNING, WARNINGS), myalgia.

Cardiovascular: hypotension and flushing.

Dermatologic: Lyell’s syndrome, Stevens-Johnson syndrome, exfoliative dermatitis, maculo-papular rash, urticaria.

Gastrointestinal: peptic ulceration, G.I. hemorrhage, G.I. perforation (see Boxed WARNING, WARNINGS), melena, acute pancreatitis.

Hemic and Lymphatic: postoperative wound hemorrhage (rarely requiring blood transfusion - see Boxed WARNING, WARNINGS and PRECAUTIONS), thrombocytopenia, leukopenia.

Hepatic: hepatitis, liver failure, cholestatic jaundice.

Nervous System: convulsions, psychosis, aseptic meningitis.

Respiratory: asthma, bronchospasm.

Urogenital: acute renal failure (see Boxed WARNING, WARNINGS), flank pain with or without hematuria and/or azotemia, nephritis, hyponatremia, hyperkalemia, hemolytic uremic syndrome.


In controlled overdosage, daily doses of 360 mg of ketorolac tromethamine injection given for five days (3 times the highest recommended dose), caused abdominal pain and peptic ulcers which healed after discontinuation of dosing. Metabolic acidosis has been reported following intentional overdosage.

Dialysis does not significantly clear ketorolac tromethamine from the blood stream.




Ketorolac tromethamine injection may be used as a single, or multiple dose, on a regular or "prn" schedule for the management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Hypovolemia should be corrected prior to the administration of ketorolac tromethamine (see WARNINGS − Renal Effects). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.

When administering ketorolac tromethamine injection the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The analgesic effect begins in ~30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of analgesic effect is usually 4 to 6 hours.

Single-Dose Treatment: The following regimen should be limited to single administration use only.

IM Dosing:

IV Dosing:

Multiple-Dose Treatment (IV or IM):

For breakthrough pain, do not increase the dose or the frequency of ketorolac tromethamine. Consideration should be given to supplementing these regimens with low doses of opioids “prn” unless otherwise contraindicated.

Pharmaceutical Information for Ketorolac Tromethamine Injection

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Ketorolac tromethamine injection should not be mixed in a small volume (e.g., in a syringe) with morphine sulfate, meperidine hydrochloride, promethazine hydrochloride or hydroxyzine hydrochloride; this will result in precipitation of ketorolac from solution.


Ketorolac Tromethamine Injection, USP 60 mg (30 mg/mL) is supplied as follows:

1 vial packaged in a pouch NDC 63739-472-21

5 pouches (NDC 63739-472-21) packaged in a carton NDC 63739-472-05

Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]

Manufactured By:
Hospira, Inc.,
Lake Forest, IL 60045 USA

Distributed By:
McKesson Packaging
Concord, NC 28027

Revised: January, 2007



Ketorolac Label

NDC 63739-472-05

2 mL Fill Single-dose

Injection, USP
60 mg (30 mg/mL)

5 Vials

Rx Only

Each mL Contains:
60 mg per 2 mL of Ketorolac Tromethamine in sterile solution

Usual dosage: See insert

Store at 20°-25°C (68° -77°F) (See USP Controlled Room Temperature).

Keep this and all medications out of the reach of children.

Mfg. By: Hospira, Inc. Lake Forest, IL 60045 USA

Dist. By: McKesson Packaging Services a business unit of McKesson Corporation
7101 Weddington Rd. Concord, NC 28027

ketorolac tromethamine injection, solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:63739-472(NDC:0409-3796)
Route of Administration INTRAMUSCULAR
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Ketorolac Tromethamine (UNII: 4EVE5946BQ) (Ketorolac - UNII:YZI5105V0L) Ketorolac Tromethamine 30 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
Alcohol (UNII: 3K9958V90M)  
Sodium Chloride (UNII: 451W47IQ8X) 8.70 mg  in 2 mL
Water (UNII: 059QF0KO0R)  
Sodium Hydroxide (UNII: 55X04QC32I)  
Hydrochloric Acid (UNII: QTT17582CB)  
# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:63739-472-05 5 in 1 BOX
1 NDC:63739-472-21 1 in 1 POUCH
1 2 mL in 1 VIAL
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA074802 05/03/2010
Labeler - McKesson Packaging Services Business Unit of McKesson Corporation (140529962)
Name Address ID/FEI Business Operations
Name Address ID/FEI Business Operations
McKesson Packaging Services Business Unit of McKesson Corporation 140529962 REPACK

Revised: 5/2010
Document Id: 7dad59b7-0ae1-4750-9122-9ab103db4bf0
Set id: 7dad59b7-0ae1-4750-9122-9ab103db4bf0
Version: 1
Effective Time: 20100503
McKesson Packaging Services Business Unit of McKesson Corporation